title: Development and optimization of a multiple-unit controlled release formulation of a freely water soluble drug for once-daily administration.
abstract: A controlled release resinate beads of betahistine diHCl (BHCl), a short half-life freely water soluble drug, was developed to allow once-daily administration to improve patient compliance and eliminate the risk of intolerance of the drug. BHCl-resin complex was subsequently coated with Eudragit RS100. A 2(4) full factorial design was employed for optimization and to explore the effect of Eudragit RS100 concentration in the coating solution (X(1)), the coating percentage (X(2)), the speed of rotation (X(3)) and the concentration of plasticizer (PEG 400) (X(4)) on the release rate of the drug from the microcapsules. The extent of coating (Y(1)), and the percentage drug released at given times (Y(2), Y(3) and Y(4)) were selected as dependent variables. The optimization process was performed for X(1), X(2), X(3) and X(4) using target ranges of these responses determined based on target release model deduced form zero-order dissolution profile of BHCl for once-daily administration. The levels of X(1), X(2), X(3) and X(4) of optimized BHCl microcapsules are 14.42%, 50.63%, 1495rpm and 9.94%, respectively. The calculated value of f(2) for the optimized BHCl microcapsules filled into hard gelatin capsules was 67.03 indicating that the dissolution profiles of the optimized formulation is comparable to that of the target release model. It could be concluded that a promising once-daily extended-release microcapsules of the highly water soluble drug, BHCl, was successfully designed.
authors.affiliation: Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Kasr El-aini street, Cairo 11562, Egypt.
authors.forename: Rehab N
authors.initials: RN
authors.lastname: Shamma
authors.forename: Emad B
authors.initials: EB
authors.lastname: Basalious
authors.forename: Raguia A
authors.initials: RA
authors.lastname: Shoukri
mesh_terms: D000284:Administration, Oral; D001621:Betahistine / Q000008:administration & dosage* / Q000737:chemistry* / Q000493:pharmacokinetics; D002214:Capsules / Q000008:administration & dosage / Q000032:analysis / Q000737:chemistry / Q000493:pharmacokinetics; D003198:Computer Simulation; D003692:Delayed-Action Preparations / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D016503:Drug Delivery Systems; D015195:Drug Design; D006801:Humans; D010316:Particle Size; D012117:Resins, Synthetic / Q000737:chemistry*; D012995:Solubility; D014665:Vasodilator Agents / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D014867:Water
chemical_list: D002214:Capsules; D003692:Delayed-Action Preparations; D012117:Resins, Synthetic; D014665:Vasodilator Agents; D014867:Water; C077982:Dowex 50; D001621:Betahistine